132 related articles for article (PubMed ID: 35815604)
1. Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia.
Dreesen E; Gijsen M; Elkayal O; Annaert P; Debaveye Y; Wauters J; Karlsson MO; Spriet I
J Antimicrob Chemother; 2022 Aug; 77(9):2479-2488. PubMed ID: 35815604
[TBL] [Abstract][Full Text] [Related]
2. Are Standard Dosing Regimens of Ceftriaxone Adapted for Critically Ill Patients with Augmented Creatinine Clearance?
Ollivier J; Carrié C; d'Houdain N; Djabarouti S; Petit L; Xuereb F; Legeron R; Biais M; Breilh D
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30602511
[TBL] [Abstract][Full Text] [Related]
3. Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study.
Hartman SJF; Upadhyay PJ; Hagedoorn NN; Mathôt RAA; Moll HA; van der Flier M; Schreuder MF; Brüggemann RJ; Knibbe CA; de Wildt SN
Clin Pharmacokinet; 2021 Oct; 60(10):1361-1372. PubMed ID: 34036552
[TBL] [Abstract][Full Text] [Related]
4. Multicenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically Ill Patients.
Heffernan AJ; Sime FB; Kumta N; Wallis SC; McWhinney B; Ungerer J; Wong G; Joynt GM; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0218921. PubMed ID: 35575578
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics and Dosing Simulations of Ceftriaxone in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (An ASAP ECMO Study).
Cheng V; Abdul-Aziz MH; Burrows F; Buscher H; Cho YJ; Corley A; Gilder E; Kim HS; Lim SY; McGuinness S; Parke R; Reynolds C; Rudham S; Wallis SC; Welch SA; Fraser JF; Shekar K; Roberts JA;
Clin Pharmacokinet; 2022 Jun; 61(6):847-856. PubMed ID: 35253107
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured versus Predicted Unbound Ceftriaxone Concentrations in Critically Ill Patients with Pneumonia: An Observational Cohort Study.
Gijsen M; Dreesen E; Van Daele R; Annaert P; Debaveye Y; Wauters J; Spriet I
Antibiotics (Basel); 2021 May; 10(5):. PubMed ID: 34064676
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamic target attainment of ceftriaxone in adult severely ill sub-Saharan African patients: a population pharmacokinetic modelling study.
Bos JC; Prins JM; Mistício MC; Nunguiane G; Lang CN; Beirão JC; Mathôt RAA; van Hest RM
J Antimicrob Chemother; 2018 Jun; 73(6):1620-1629. PubMed ID: 29522167
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic/pharmacodynamic target attainment of ceftriaxone 2 g once daily in non-critically ill hospitalized adult patients during the acute phase of infection.
van den Broek AK; van Schip A; Visser CE; Bos JC; Prins JM; van Hest RM
Br J Clin Pharmacol; 2023 Nov; 89(11):3262-3272. PubMed ID: 37309251
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of unbound ceftriaxone in a critically ill population.
Meenks SD; le Noble JLML; Foudraine NA; de Vries F; Neef K; Janssen PKC
Int J Clin Pharmacol Ther; 2022 Sep; 60(9):373-383. PubMed ID: 35861497
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients.
Joynt GM; Lipman J; Gomersall CD; Young RJ; Wong EL; Gin T
J Antimicrob Chemother; 2001 Apr; 47(4):421-9. PubMed ID: 11266414
[TBL] [Abstract][Full Text] [Related]
11. Once-daily 1 g ceftriaxone optimizes exposure in patients with septic shock and hypoalbuminemia receiving continuous veno-venous hemodiafiltration.
Ulldemolins M; Bastida C; Llauradó-Serra M; Csajka C; Rodríguez A; Badia JR; Martín-Loeches I; Soy D
Eur J Clin Pharmacol; 2021 Aug; 77(8):1169-1180. PubMed ID: 33559708
[TBL] [Abstract][Full Text] [Related]
12. Validating a novel three-times-weekly post-hemodialysis ceftriaxone regimen in infected Indigenous Australian patients-a population pharmacokinetic study.
Tsai D; Zam BB; Tongs C; Chiong F; Sajiv C; Pawar B; Ashok A; Cooper BP; Tong SYC; Janson S; Wallis SC; Roberts JA; Parker SL
J Antimicrob Chemother; 2023 Aug; 78(8):1963-1973. PubMed ID: 37367723
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of ceftriaxone administered as continuous or intermittent infusion in critically ill patients.
Leegwater E; Kraaijenbrink BVC; Moes DJAR; Purmer IM; Wilms EB
J Antimicrob Chemother; 2020 Jun; 75(6):1554-1558. PubMed ID: 32129853
[TBL] [Abstract][Full Text] [Related]
14. Ceftriaxone dosing in patients admitted from the emergency department with sepsis.
Heffernan AJ; Curran RA; Denny KJ; Sime FB; Stanford CL; McWhinney B; Ungerer J; Roberts JA; Lipman J
Eur J Clin Pharmacol; 2021 Feb; 77(2):207-214. PubMed ID: 32974748
[TBL] [Abstract][Full Text] [Related]
15. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.
Ulldemolins M; Roberts JA; Rello J; Paterson DL; Lipman J
Clin Pharmacokinet; 2011 Feb; 50(2):99-110. PubMed ID: 21142293
[TBL] [Abstract][Full Text] [Related]
16. Plasma protein binding of ceftriaxone in critically ill patients: can we predict unbound fractions?
Ewoldt TMJ; Bahmany S; Abdulla A; Muller AE; Endeman H; Koch BCP
J Antimicrob Chemother; 2023 Apr; 78(4):1059-1065. PubMed ID: 36849582
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetic Modeling of Total and Free Ceftriaxone in Critically Ill Children and Young Adults and Monte Carlo Simulations Support Twice Daily Dosing for Target Attainment.
Tang Girdwood S; Dong M; Tang P; Stoneman E; Jones R; Yunger T; Ostermeier A; Curry C; Forton M; Hail T; Mullaney R; Lahni P; Punt N; Kaplan J; Vinks AA
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0142721. PubMed ID: 34633847
[TBL] [Abstract][Full Text] [Related]
18. Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients.
Schleibinger M; Steinbach CL; Töpper C; Kratzer A; Liebchen U; Kees F; Salzberger B; Kees MG
Br J Clin Pharmacol; 2015 Sep; 80(3):525-33. PubMed ID: 25808018
[TBL] [Abstract][Full Text] [Related]
19. Total and unbound ceftriaxone pharmacokinetics in critically ill Australian Indigenous patients with severe sepsis.
Tsai D; Stewart P; Goud R; Gourley S; Hewagama S; Krishnaswamy S; Wallis SC; Lipman J; Roberts JA
Int J Antimicrob Agents; 2016 Dec; 48(6):748-752. PubMed ID: 27838278
[TBL] [Abstract][Full Text] [Related]
20. Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT).
Abdulla A; Dijkstra A; Hunfeld NGM; Endeman H; Bahmany S; Ewoldt TMJ; Muller AE; van Gelder T; Gommers D; Koch BCP
Crit Care; 2020 Sep; 24(1):558. PubMed ID: 32933574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
